| Project/Area Number |
23659072
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
宮田 昌明 東北大学, 薬学研究科(研究院), 助教 (90239418)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 医薬品情報 / 安全性学 / 薬剤性肝障害 / マクロファージ / 肝非実質細胞 / 核内受容体 / 炎症 / 転写調節 |
|---|
| Research Abstract |
In this study, we have investigated the influences of treatment with the activators of inflammation-associated nuclear receptors on the gene expression profile of inflammation-related genes in human model macrophages and rat Kupffer cells. The results suggest that the activation of either PXR, CAR, LXRα, PPAR or PPARγ elicits the changes in the gene expression of the several genes investigated, that the influence is dependent on the nuclear receptors, and that the changes are regulated at the transcriptional levels. These imply that not only parenchymal hepatocytes but non-parenchymal hepatocytes are targets for the drug- or xenobiotic-induced liver inflammation.
|
